Kei Ikeda

29PUBLICATIONS
117CO-AUTHORS
AvionicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 27, 2026
Autoantibodies against adenosine deaminase acting on RNA1 (ADAR1) in patients with systemic lupus erythematosus: its relationship to clinical features and other autoantibodies.

|Jun 26, 2026
Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

|Jan 29, 2026
Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Jan 28, 2026
A Case of IgG4-Related Disease That Mimics an Anterior Mediastinal Malignant Tumour.

Noriaki Nishimura, Yusuke Nakamura, Nana Yazawa

|Oct 25, 2025
Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Jun 14, 2025
Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.

Koji Suzuki, Hideto Kameda, Kei Ikeda

Pageof 5

Frequent Collaborators

6 joint publications

Yoshiya Tanaka

6 joint publications

Hiroshi Nakajima

6 joint publications

Yuko Kaneko

5 joint publications

Hideto Kameda